Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06389071

Laser Treatment for Lichen Sclerosus

Fractional ablative laser treatment for Lichen Sclerosus lesion

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Clinique Medicale Uro-Gyneco de l'Abitibi

Val-d'Or, Quebec, J9P1W1, Canada

Location status: Recruiting

Location contact

Josee Parent, MD

CONTACT

819-825-3800

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female aged 18 years or older
  • Biopsy-proven vulvar lichen sclerosus lesion
  • Experiencing one or more of the following symptoms of LS:
  • Dryness
  • Itching
  • Burning
  • Bleeding
  • Blistering
  • Soreness
  • Easily bruises
  • Easily tears
  • Ulcerated lesions
  • Painful intercourse
  • Negative urine pregnancy test if subject is of childbearing potential before enrollment
  • Absence of vulvovaginal infection i.e. fungi, bacterial vaginosis, and STI
  • Ability to understand and sign informed consent, questionnaires, and all investigation requirements
  • Willing to consent to clinical photographs of the treatment area
  • Willing to consent to ultrasound images of the treatment area
  • Willing and able to logistically follow schedule of treatments and follow-up visits

Exclusion criteria

  • Pregnancy, less than 3 months postpartum, or planning to become pregnant during the investigation to protect integrity of the data
  • Is a nursing mother
  • History of uncontrolled malignant disease
  • Active urogenital infection or chronic infection (i.e., candida, herpes, herpes simplex, bacterial vaginosis, trichomoniasis, or other infection)
  • Immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich syndrome)
  • Subjects with genital skin disease, psoriasis due to risk of koeberizing
  • Subjects on immunosuppressants: mycophenolate, retinoids, azathioprine, cyclosporin
  • Known allergy or intolerance to local anesthesia
  • Known history of connective tissue disease
  • Known propensity for keloid formations
  • Known medical condition that may affect wound healing
  • Any reason that the investigator deems prohibits participation in the investigation

Treatment and study plan

Fractional 2940 nm Laser

Device

Fractional 2940 nm Laser

Primary outcomes

  1. Histological clearance

    Time frame: 16 weeks

    Efficacy of the treatment is determined by histological changes measured at 16 weeks post final treatment

Study contacts

Contact information is provided by the study sponsor or research team.

J Patel

CONTACT

[email protected]

6504939155

Sponsors and collaborators

Lead sponsor

Sciton

Industry

Registry information

Official study title

Safety and Efficacy of Ablative Fractional 2940 nm Laser Treatment for Lichen Sclerosus Lesion

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Apr 29, 2024
Registry last updated
Apr 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.